IN THE CLAIMS:

Please amend claims 1, 7, and 11 and add new claim 12:

A 2

1. (AMENDED) A compound of the formula I,



I

wherein

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, or 3;

A is halogen;

X is sulfur or oxygen;

R^1 is chosen from hydrogen, hydroxy, (C_1-C_{12})-alkoxycarbonyl-, (C_6-C_{14})-aryl-(C_1-C_4)-alkoxycarbonyl-, and (C_6-C_{14})-aryloxycarbonyl-, wherein each of the aryl groups is unsubstituted or substituted by at least one identical or different substituent chosen from (C_1-C_{12})-alkyl, halogen and (C_1-C_{12})-alkoxy;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

A2

R^2 is chosen from hydrogen, (C_1-C_{12})-alkyl, (C_6-C_{14})-aryl, (C_6-C_{14})-aryl-(C_1-C_4)-alkyl-, R^{20}-(C_1-C_{12})-alkyl-, R^{20}-(C_6-C_{14})-aryl-, and R^{20}-(C_6-C_{14})-aryl-(C_1-C_4)-alkyl-, wherein R^{20} is chosen from hydroxycarbonyl-, aminocarbonyl-, (C_1-C_{12})-alkoxycarbonyl-, and (C_6-C_{14})-aryl-(C_1-C_4)-alkoxycarbonyl-;

R^3 is chosen from hydrogen, cyano, hydroxy, and (C_1-C_{12})-alkyl;

R^4 is chosen from (C_1-C_{12})-alkyl, (C_6-C_{14})-aryl, (C_6-C_{14})-aryl-(C_1-C_4)-alkyl-, Het, and Het-(C_1-C_4)-alkyl-, wherein the alkyl, aryl and Het groups are unsubstituted or substituted by at least one identical or different substituent R^{10};

R^5 is chosen from hydrogen, (C_1-C_{12})-alkyl, (C_6-C_{14})-aryl, (C_6-C_{14})-aryl-(C_1-C_4)-alkyl-, Het, Het-(C_1-C_4)-alkyl-, (C_6-C_{14})-aryl-(C_1-C_4)-alkyl-aminocarbonyl-, and Het-(C_1-C_4)-alkyl-aminocarbonyl-, wherein the alkyl, aryl and Het groups are unsubstituted or substituted by at least one identical or different substituent R^{10};

or

R^4 and R^5 together with the carbon atom to which they are bonded form a saturated or unsaturated 3-membered to 8-membered ring which is a carbocyclic ring or a heterocyclic ring containing 1, 2 or 3 identical or different ring heteroatoms chosen from nitrogen, oxygen and sulfur, and which is optionally condensed to one or two saturated or unsaturated

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

A2

carbocyclic ring systems or heterocyclic ring systems containing 5 to 10 ring atoms of which 1, 2 or 3 are identical or different ring heteroatoms chosen from nitrogen, oxygen and sulfur, wherein the resulting $R^4(R^5)C$ group is unsubstituted or substituted by at least one identical or different substituent R^{10};

R^6 is chosen from hydrogen, hydroxy, (C_1-C_8)-alkoxy, and (C_6-C_{14})-aryl-(C_1-C_4)-alkoxy-;

R^{10} is chosen from (C_1-C_{12})-alkyl, (C_6-C_{14})-aryl-(C_1-C_4)-alkyl-, (C_1-C_8)-alkoxy, (C_1-C_4)-alkoxy-(C_2-C_4)-alkoxy-, (C_6-C_{14})-aryl-(C_1-C_4)-alkoxy-, (C_6-C_{14})-aryloxy-, Het-oxy-, Het-(C_1-C_4)-alkoxy-, (C_6-C_{14})-aryl, Het, Het-(C_1-C_4)-alkyl-, trifluoromethoxy, trifluoromethyl, halogen, oxo, hydroxy, amino, (C_1-C_{12})-alkylcarbonylamino-, aminocarbonylamino-, (C_6-C_{14})-arylcarbonylamino-, Het-carbonylamino-, (C_6-C_{14})-aryl-(C_1-C_4)-alkylcarbonylamino-, Het-(C_1-C_4)-alkylcarbonylamino-, (C_1-C_8)-alkylcarbonyl-, (C_6-C_{14})-arylcarbonyl-, (C_1-C_8)-alkylaminocarbonyl-, (C_6-C_{14})-arylaminocarbonyl-, (C_6-C_{14})-aryl-(C_1-C_4)-alkylaminocarbonyl-, Het-aminocarbonyl-, Het-(C_1-C_4)-alkylaminocarbonyl-, aminocarbonyl-, (C_1-C_8)-alkoxycarbonyl-, hydroxycarbonyl-, cyano, nitro, amidino, acetimino, tri-$((C_1-C_4)$-alkyl)ammonio-, (C_1-C_8)-alkylamino-, di-$((C_1-C_8)$-alkyl)amino-, hydroxycarbonylmethoxy-, (C_1-C_8)-alkylsulfonyl-, (C_6-C_{14})-arylsulfonyl-, (C_1-C_8)-alkylaminosulfonyl-, (C_6-C_{14})-arylaminosulfonyl-, (C_6-C_{14})-aryl-(C_1-C_4)-alkylaminosulfonyl-, Het-aminosulfonyl-, Het-(C_1-C_4)-

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

A 2

alkylaminosulfonyl-, (C_1-C_8)-alkylsulfonylamino-, (C_6-C_{14})-arylsulfonylamino-, (C_6-C_{14})-aryl-(C_1-C_4)-alkylsulfonylamino-, Het-sulfonylamino-, and Het-(C_1-C_4)-alkylsulfonylamino-, wherein (C_1-C_{12})-alkylcarbonylamino- representing R^{10} is unsubstituted or substituted in the alkyl group by a substituent chosen from amino, hydroxy and (C_1-C_4)-alkoxy, and wherein (C_1-C_{12})-alkyl and (C_1-C_8)-alkoxy representing R^{10} are unsubstituted or substituted by at least one identical or different substituent chosen from (C_1-C_8)-alkoxycarbonyl-, hydroxycarbonyl- and aminocarbonyl-,

wherein each of the aryl groups and Het group in a group R^{10} is unsubstituted or substituted by at least one identical or different substituent chosen from halogen, nitro, oxo, hydroxy, (C_1-C_8)-alkyl, (C_1-C_8)-alkoxy, (C_1-C_4)-alkoxy-(C_2-C_4)-alkoxy-, (C_6-C_{14})-aryloxy-, (C_6-C_{14})-aryl-(C_1-C_4)-alkoxy-, Het-oxy-, Het-(C_1-C_4)-alkoxy-, (C_6-C_{14})-aryl, (C_6-C_{14})-aryl-(C_1-C_4)-alkyl-, Het, Het-(C_1-C_4)-alkyl-, trifluoromethyl, cyano, trifluoromethoxy, (C_1-C_8)-alkylsulfonyl-, (C_1-C_8)-alkoxycarbonyl-, hydroxycarbonyl-, aminocarbonyl-, amino, (C_1-C_8)-alkylamino-, di-((C_1-C_8)-alkyl)amino-, (C_1-C_8)-alkylcarbonylamino-, (C_6-C_{14})-aryl-(C_1-C_4)-alkylcarbonylamino-, (C_6-C_{14})-arylcarbonylamino-, Het-carbonylamino-, Het-(C_1-C_4)-alkylcarbonylamino-, and (C_1-C_8)-alkylcarbonyl-, wherein (C_1-C_8)-alkyl and (C_1-C_8)-alkoxy representing a substituent on an aryl group or Het group in a group R^{10} are unsubstituted or substituted by at least one

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

identical or different substituent chosen from (C_1-C_8)-alkoxycarbonyl-, hydroxycarbonyl- and aminocarbonyl-,

A2

with the proviso that, when a substituent R^{10} is bonded to an alkyl group, it cannot be (C_1-C_8)-alkoxycarbonyl-, hydroxycarbonyl-, aminocarbonyl-, (C_1-C_8)-alkylaminocarbonyl-, or (C_1-C_8)-alkylaminosulfonyl-, and that, when a substituent R^{10} is bonded to an alkyl group, it cannot be (C_1-C_8)-alkyl which is substituted by at least one identical or different substituent chosen from (C_1-C_8)-alkoxycarbonyl-, hydroxycarbonyl- and aminocarbonyl-;

Het is a residue of a saturated or unsaturated monocyclic or bicyclic, 3-membered to 10-membered heterocyclic ring system containing 1, 2 or 3 identical or different ring heteroatoms chosen from nitrogen, oxygen and sulfur;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

A3

7. (AMENDED) A process for the preparation of at least one compound of formula I as claimed in claim 1, comprising linking the compounds of formulae II, III and IV with formation of a (thio)urea bridge between the groups G^1 and G^2 in formulae II and III and an amide bond between the COZ group in formula II and the NH2 group in formula IV,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

A3



II



III



IV

wherein

(a) G^1 is NH_2 and G^2 is chosen from iso(thio)cyanato, $(C_1$-$C_6)$-alkoxycarbonylamino, trichloromethylcarbonylamino, and azolyl-N-(thio)carbonylamino, wherein these groups contain the group R^6; or

(b) G^1 is chosen from iso(thio)cyanato, $(C_1$-$C_6)$-alkoxycarbonylamino, trichloromethylcarbonylamino, and azolyl-N-(thio)carbonylamino and G^2 is NHR^6; and

Z in the compound of formula III is chosen from hydroxy and a nucleophilically substitutable leaving group; R^0 in the compound of formula II is chosen from R^1NH-C(=NH)-, a protected form thereof, and a precursor group thereof; and m, n, A, R^1, R^2, R^3, R^4, R^5 and R^6 are defined as in claim 1, but wherein functional groups can also be present in protected form or in the form of precursor groups.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

11. (AMENDED) A method of inhibiting or reducing blood clotting or inflammatory response, comprising administering to a patient an effective amount